Effect of Metabolic Dysfunction in Branched-chain Amino Acids on Cardiac Function in Patients With Sepsis
- Conditions
- Sepsis
- Interventions
- Other: Effect of BCAAs metabolic dysfunction on cardiac function in sepsis
- Registration Number
- NCT06258252
- Lead Sponsor
- West China Hospital
- Brief Summary
The current project was designed to examine the effects of BCAA metabolic dysfunction on cardiac function in septic patients.
- Detailed Description
Patients with sepsis and with/without type 2 diabetes will be included. Patients prospectively collected the following indicators in the intensive care unit: 1. myocardial injury-related biomarkers: troponin T and B natriuretic peptide levels; 2. cardiac structure-related indicators: the size of the left and right ventricle, left ventricular ejection fraction, etc.3. septic cardiomyopathy incidence: Troponin T\>0.01ng/ml is the standard for the diagnosis of septic cardiomyopathy. Additionally, the investigators will collect the peripheral blood at preoperative, day 1, day 3, and day 5 after surgery. Peripheral blood plasma and PBMCs were separated by differential centrifugation: the concentration of BCAAs in serum and PBMCs; the expression of PBMCs BCAAs metabolic enzymes BCAT 1, BCKDH, and PP 2 Cm by WB; and the levels of AST, ALT, LDH, CK, and CK-MB
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 50
- patients diagnosed with sepsis with or without type 2 diabetes
- patients with immunodeficient diseases patients who accept glucocorticoid or immunosuppressant patients with an age younger than 18 years patients who cannot provide informed consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients who are diagnosed as sepsis, with type 2 diabetes. Effect of BCAAs metabolic dysfunction on cardiac function in sepsis 1. myocardial injury-related biomarkers: troponin T and B natriuretic peptide levels; 2. cardiac structure-related indicators: the size of the left and right ventricle, left ventricular ejection fraction, etc.3. septic cardiomyopathy incidence: Troponin T\>0.01ng/ml is the standard for the diagnosis of septic cardiomyopathy. Patients who are diagnosed as sepsis, without type 2 diabetes. Effect of BCAAs metabolic dysfunction on cardiac function in sepsis 1. myocardial injury-related biomarkers: troponin T and B natriuretic peptide levels; 2. cardiac structure-related indicators: the size of the left and right ventricle, left ventricular ejection fraction, etc.3. septic cardiomyopathy incidence: Troponin T\>0.01ng/ml is the standard for the diagnosis of septic cardiomyopathy.
- Primary Outcome Measures
Name Time Method The incidence of Sepsis induced cardiomyopathy up to 7 days post-ICU admission, or at hospital discharge, whichever comes first Diagnostic criteria for Sepsis induced cardiomyopathy, TroponinT \> 0.01 ng/ml
- Secondary Outcome Measures
Name Time Method Plasma levels of type B natriuretic peptide up to 7 days post-ICU admission, or at hospital discharge, whichever comes first If multiple measurements is available during the first 7 days, the mean measurement will be used for analysis.
Plasma levels of TroponinT up to 7 days post-ICU admission, or at hospital discharge, whichever comes first If multiple measurements is available during the first 7 days, the mean measurement will be used for analysis.
Left ventricular and right ventricular size up to 7 days post-ICU admission, or at hospital discharge, whichever comes first If multiple measurements is available during the first 7 day, the mean measurement will be used for analysis.
ejection fraction up to 7 days post-ICU admission, or at hospital discharge, whichever comes first If multiple measurements is available during the first 7 day, the mean measurement will be used for analysis.